ArticleTranslational cancer research2026
Efficacy of nab-paclitaxel combined with immune checkpoint inhibitors in solid tumors: a systematic review and meta-analysis of randomized controlled trials.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nab-paclitaxel combined with immune checkpoint inhibitors (ICIs) is a promising strategy across solid tumors, but its overall efficacy across cancer types and treatment settings remains to be comprehensively quantified. We therefore aimed to evaluate the efficacy of nab-paclitaxel plus ICIs versus nab-paclitaxel-based regimens without immunotherapy across multiple solid tumor types and treatment settings. Methods: PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science were searched through January 1, 2026, for randomized controlled trials (RCTs) comparing nab-paclitaxel plus ICIs with nab-paclitaxel-based therapy without ICIs. Primary outcomes were overall survival (OS), progression-free survival (PFS), and pathological complete response (pCR). Secondary outcomes included objective response rate (ORR) and disease control rate (DCR). Pooled hazard ratios (HRs) and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. Subgroup analyses were performed by cancer type and ICI class. Results: Twenty-four RCTs enrolling 6,682 patients across five tumor types [non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), pancreatic ductal adenocarcinoma (PDAC), gastric cancer, and esophageal squamous cell carcinoma (ESCC)] were included. Nab-paclitaxel plus ICIs significantly improved OS (HR =0.79; 95% CI: 0.73-0.84), PFS (HR =0.63; 95% CI: 0.58-0.69), and pCR (RR =1.28; 95% CI: 1.15-1.43) compared with controls. ORR (RR =1.33; 95% CI: 1.20-1.47) and DCR (RR =1.15; 95% CI: 1.02-1.29) were also improved. Subgroup analyses showed consistent OS benefits across all cancer types (P=0.70) and ICI classes. Anti-programmed cell death protein 1 (PD-1) agents showed significantly greater PFS benefit than anti-programmed death-ligand 1 (PD-L1) agents (P=0.02). Sensitivity analyses confirmed robustness of all estimates. Conclusions: Nab-paclitaxel combined with ICIs significantly improves survival, tumor response, and pCR across multiple solid tumors. These findings support the broad applicability of this combination and highlight the value of anti-PD-1-based regimens in optimizing PFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.